Targeting cAMP/PKA pathway for glycemic control and type 2 diabetes therapy

J Mol Endocrinol. 2016 Aug;57(2):R93-R108. doi: 10.1530/JME-15-0316. Epub 2016 May 18.

Abstract

In mammals, cyclic adenosine monophosphate (cAMP) is an intracellular second messenger that is usually elicited by binding of hormones and neurotransmitters to G protein-coupled receptors (GPCRs). cAMP exerts many of its physiological effects by activating cAMP-dependent protein kinase (PKA), which in turn phosphorylates and regulates the functions of downstream protein targets including ion channels, enzymes, and transcription factors. cAMP/PKA signaling pathway regulates glucose homeostasis at multiple levels including insulin and glucagon secretion, glucose uptake, glycogen synthesis and breakdown, gluconeogenesis, and neural control of glucose homeostasis. This review summarizes recent genetic and pharmacological studies concerning the regulation of glucose homeostasis by cAMP/PKA in pancreas, liver, skeletal muscle, adipose tissues, and brain. We also discuss the strategies for targeting cAMP/PKA pathway for research and potential therapeutic treatment of type 2 diabetes mellitus (T2D).

Keywords: PKA; diabetes; glucagon; glucose; insulin.

Publication types

  • Review
  • Research Support, N.I.H., Extramural

MeSH terms

  • Animals
  • Blood Glucose*
  • Cyclic AMP / metabolism*
  • Cyclic AMP-Dependent Protein Kinases / metabolism*
  • Diabetes Mellitus, Type 2 / metabolism*
  • Diabetes Mellitus, Type 2 / therapy*
  • Glucagon / metabolism
  • Glucose / metabolism
  • Homeostasis
  • Humans
  • Insulin / metabolism
  • Islets of Langerhans / metabolism
  • Liver / metabolism
  • Molecular Targeted Therapy
  • Muscle, Skeletal / metabolism
  • Organ Specificity
  • Signal Transduction*

Substances

  • Blood Glucose
  • Insulin
  • Glucagon
  • Cyclic AMP
  • Cyclic AMP-Dependent Protein Kinases
  • Glucose